Juan Wang

Juan Wang

Auto-generated profile, based on publicly available information

Juan Wang

Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2021 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
RLRui Li
Rui Li
XLXiaolei Liu
Xiaolei Liu
GCGuangliang Chen
Guangliang Chen
GTGuo Tang
Guo Tang
XCXiaoxiang Chen
Xiaoxiang Chen
LLLiang-Jing Lu
Liang-Jing Lu
Objectives: To define different clinical phenotypes and assess prognostic factors of adult-onset Still’s disease (AOSD). Methods: Overall, 492 patients with AOSD seen between 2004 and 2018 at a single centre were retrospectively studied. Results: Of these patients, 78% were female, and the median age at onset was 34 (25–49) years [median (25th–75th percentile)]. The median follow-up time was 7 (3–10) years [median (25th–75th percentile)]. Clinical manifestations at admission were used to subdivide patients with AOSD as follows: systemic inflammation (cluster 1), pure (cluster 2), and intermediate (cluster 3). Each subtype had distinct clinical manifestations and prognoses: cluster 1 (34.6%)—multiple organ manifestations, highest infection rate and mortality, and more than half of the patients with at least one relapse during follow-up; cluster 2 (21.3%)—exclusively female, rash and joint involvement, no internal organ involvement, no mortality, and most of the patients with a monocyclic course; and cluster 3 (44.1%)—less infection rate, no serious complications, and lower mortality rate. The 5- and 10-year survival rates after diagnosis were 92.4% and 86.9%, respectively. Independent risk factors for mortality were age at onset ≥50 (hazard ratio (HR): 6.78, 95% CI: 2.10–21.89), hepatomegaly (HR: 5.05, 95% CI: 1.44–17.70), infection (HR: 15.56, 95% CI: 5.88–41.20), and MAS (HR: 26.82, 95% CI: 7.52–95.60). Conclusion: Three subtypes of AOSD were identified with distinct clinical manifestations and prognoses. Age at onset ≥50, hepatomegaly, infection, and MAS were prognostic factors for AOSD mortality.

29 August 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
WWWenyi Wu
Wenyi Wu
JWJuan Wang
Juan Wang
SCSheng Chen
Sheng Chen
Objective: Rituximab remains the standard-of-care anti-CD20 therapy for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Obinutuzumab, a next-generation, glycoengineered anti-CD20 monoclonal antibody with enhanced B-cell-depleting capacity, may offer superior efficacy. We evaluated the efficacy and safety of reduced-dose obinutuzumab in 16 patients with active, refractory AAV at a single center in China.Methods: In this retrospective chart review, we evaluated 16 consecutive patients who received reduced-dose obinutuzumab (most commonly 1,000 mg for induction) after failure to achieve remission with cyclophosphamide (CTX) and/or rituximab (RTX) or who presented with severe, treatment-naïve disease. Primary endpoints were complete remission (CR) rates at 24 and 76 weeks. Secondary endpoints included changes in renal function, inflammatory biomarkers, and immune reconstitution. Adverse events were prospectively recorded.Results: The median age at obinutuzumab initiation was 44.5 years (IQR 31–54.3); 10 (62.5%) were men. The mean Birmingham Vasculitis Activity Score (BVAS) was 13.5 ± 6.4. There were 12 patients (75%) who had relapsing disease refractory to CTX/RTX, whereas four treatment-naïve patients presented with multiorgan failure. CR was achieved in 8/16 patients (50%) at week 24 and 13/16 patients (81.3%) at week 76. Obinutuzumab induced rapid clinical remission, suppressed systemic inflammation, achieved peripheral B-cell depletion, rendered ANCA-negative, and improved renal and pulmonary outcomes. No severe infections occurred. Seven patients (43.8%) developed treatment-emergent infections, predominantly respiratory (75%).Conclusion: Reduced-dose obinutuzumab demonstrates sustained remission in refractory or relapsing active AAV, achieving high long-term remission rates with an acceptable safety profile. No severe invasive infections were observed.

1 October 2016
Verified
Conference Paper
Closed access
JYJing Yao
Jing Yao
YZYang Zhang
Yang Zhang
JWJuan Wang
Juan Wang
An effective pressure estimation algorithm of ABS for motorcycles was proposed in this paper to get the relatively accurate wheel cylinder pressure. Firstly, the performance characteristics of hydraulic control unit was studied and the vehicle model was established by using BikeSim. Next, the pressure estimation algorithms of master cylinder and wheel cylinder were studied. The estimated pressure is modified according to different vehicle braking stages. Finally, based on an actual motorcycle the wheel cylinder pressure was obtained under different pavements and braking initial speeds by ABS experimental platform to validate the effectiveness of wheel cylinder pressure estimation algorithm. The results show that the actual wheel cylinder pressure can be well tracked by the estimated wheel cylinder pressure with an allowable pressure error.

2 January 2025 in RMD Open
Verified
Journal Article
Open access
PDF file
QDQing Dai
Qing Dai
AXAntao Xu
Antao Xu
YYYan Ye
Yan Ye
CLChenyin Lv
Chenyin Lv
HLHuaxiang Liu
Huaxiang Liu
JWJuan Wang
Juan Wang
Objective The objective of this study is to evaluate the efficacy and safety of jaktinib hydrochloride tablets (jaktinib), a Janus kinase inhibitor, in patients with active radiographic axial spondyloarthritis (r-axSpA). Methods Adults with active r-axSpA who met modified New York criteria and had an inadequate response to non-steroidal anti-inflammatory drugs were randomised 1:1:1 to receive jaktinib 75 mg two times per day, 100 mg two times per day, or placebo. The primary and key secondary endpoints were Assessment of SpondyloArthritis international Society 20 (ASAS 20) and ASAS 40 responses, respectively, at week 16. Safety was evaluated by analysing adverse events. Results A total of 107 patients with active r-axSpA were randomised (jaktinib 75 mg two times per day, n=35; jaktinib 100 mg two times per day, n=36; placebo, n=36). In the ASAS20 response rates, the 100 mg two times per day group had the highest response at 61.1%, followed by the 75 mg two times per day group at 57.1%, and the placebo group had the lowest at 33.3% for the 16 weeks of treatment. The ASAS40 response rates were significantly higher with jaktinib (100 mg two times per day group: 47.2%, 75 mg two times per day group: 37.1%) compared with placebo (13.9%). The incidence of treatment-emergent adverse events in the 75 mg two times per day, 100 mg two times per day and placebo groups was 88.6% versus 94.4% versus 86.1%, respectively, with no statistically significant difference among the three groups. No major adverse cardiovascular events, malignancy, thromboembolism or deaths were reported. Conclusions Jaktinib showed good efficacy and tolerability in the treatment of active r-axSpA, with the 100 mg two times per day showing a trend towards better efficacy. Trial registration number NCT04507659.

28 November 2025 in BMC Rheumatology
Verified
Journal Article
Open access
PDF file
WWWenyi Wu
Wenyi Wu
JWJuan Wang
Juan Wang
SCSheng Chen
Sheng Chen
To evaluate the effectiveness and safety of rituximab (RTX) compared to cyclophosphamide (CYC) in inducing remission with ANCA-associated vasculitis (AAV).

1 July 2026 in RMD Open
Verified
Journal Article
Open access
PDF file
JWJuan Wang
Juan Wang
YYYe Yu
Ye Yu
RLRui Li
Rui Li
BSBisheng Shi
Bisheng Shi
WWWenyi Wu
Wenyi Wu
SCSheng Chen
Sheng Chen
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a leading cause of rapidly progressive glomerulonephritis (RPGN; defined as an estimated glomerular filtration rate (eGFR) decline ≥50% within 3 months), which is associated with significant morbidity and mortality.1 Induction with cyclophosphamide (CyC) or rituximab (RTX) is the current standard of care for controlling systemic inflammation in AAV,2 yet reversal of renal function impairment in RPGN is frequently limited, often making permanent nephron loss inevitable. For example, a report focusing on AAV-RPGN using CyC/RTX-based induction (with or without the addition of avacopan, a C5aR inhibitor), renal functional improvements are generally limited to approximately 20 mL/min/1.73 m².3 Thus, based on the concept of profound B-cell depletion and immune reset, and inspired by previous case reports demonstrating that CD19 CAR-T therapy and T-cell engagers (TCEs) can induce remission in patients with non-renal refractory AAV,4–7 we here report two cases of AAV-RPGN treated with blinatumomab as first-line B-cell depleting induction therapy, with a maximum follow-up of 52 weeks.